The World Health Organization will decide on providing emergency use lists to Covaxin – an indigenously developed vaccine against the coronavirus in India – next week. It comes nearly a week after the United Nations body delayed the emergency use authorization (EUA) for Covaxin as the global body sent more technical queries to its maker Bharat Biotech.
The UN’s international public health agency said in a series: “WHO and an independent group of experts are due to meet next week to assess the risk/benefit and make a final decision on whether to list Covaxin as an emergency use.” to go or not.” of tweets.
WHO and an independent group of experts are due to meet next week to assess the risk/benefit and make a final decision on whether to list Covaxin as an emergency use.#COVID-19pic.twitter.com/jJyS1hiz44
— World Health Organization (WHO) (@WHO) 5 October 2021
Another tweet read, Bharat Biotech is submitting data to WHO on an ongoing basis and additional information is being submitted at the request of WHO.
“WHO experts are currently reviewing this information and if it addresses all questions raised, the WHO assessment will be finalized next week,” the tweet said.
Without the EUA, Covaxin would not be considered a vaccine approved by most countries around the world. WHO’s queries to Bharat Biotech came despite the Hyderabad-based drugmaker’s claim that it has submitted all the data required for approval. According to him, the Phase III clinical trials of Covaxin had demonstrated an efficacy rate of 77.8%.
Covaxin, along with Covishield, was deployed for the first time by India in its massive nationwide vaccination campaign against coronavirus launched in January this year. Others, such as the Russian-made Sputnik, were added to the country’s arsenal only later. Covishield, manufactured by Serum Institute of India and developed by researchers from Oxford and AstraZeneca, is now the only India-made vaccine on the WHO’s list.